Citations

Mayo Clinic

Showing 10 of 108602 citations.

Abstract 6569: ClinGen Somatic and CIViC collaborate to comprehensively evaluate somatic variants in cancer
Danos, Arpad , Krysiak, Kilannin, McMichael, Joshua F. , Xu, Xinjie , Kanagal‐Shamanna, Rashmi , Satgunaseelan, Laveniya , Akkari, Yassmine, Raca, Gordana , Roy, Angshumoy , Kanagal-Shamanna, Rashmi , Satgunaseelan, Laveniya , Saliba, Jason , Coffman, Adam , Kiwala, Susanna , Grisdale, Cameron J. , King, Ian F. G. , Selvarajah, Shamini , Meredith, David M. , Evans, Mark G. , Mullighan, Charles G. , Wagner, Alex H. , Govindan, Ramaswamy , Griffith, Obi L. , Griffith, Malachi

Cancer Research | April 4, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 6569-6569

10.1158/1538-7445.am2023-6569 Get It

Abstract The comprehensive evaluation of somatic variants in cancer requires consensus interpretation of their potential clinical significance (diagnosis, prognosis, and treatment response) and oncogenicity. To aid precision medicine through public interpretations, a multifaceted collaborative effort is required to bring together a community, structured guidance, and a public platform. The over 200 multi-disciplinary experts in the Clinical Genome Resource (ClinGen) Somatic Cancer Clinical Domain Working Group (CDWG) provide a community that develops data curation guidelines and standards and curates evidence to determine the clinical significance and oncogenicity of somatic alterations in cancer. The Somatic CDWG established the Pediatric Cancer, Hematological Cancer, and Solid Tumor Taskforces to facilitate membership growth and targeted curation projects. Within these Taskforces, Somatic Cancer Variant Curation Expert Panels (SC-VCEPs) are developed through a 4-step approval process adapted from ClinGen germline VCEP procedures. Five SC-VCEPs (NTRK-fusions, FGFR variants, FLT3 variants, Histone H3 variants, and BCR::ABL1-like B-ALL alterations) are working through the approval process and one (Established Significance) is in the planning stage. SC-VCEPs tailor AMP/ASCO/CAP [PMID:27993330] and ClinGen/CGC/VICC Oncogenicity [PMID:35101336] guidelines, or create new classification guidance to aid granular assessment of their genomic alterations of interest. The Clinical Interpretations of Variants in Cancer (CIViC) knowledgebase provides the public platform for the Taskforces and SC-VCEPs to display their high-quality somatic cancer variant interpretations. These groups curate evidence from published literature and create Assertions summarizing evidence collected. These Assertions are further disseminated through other resources like ClinVar and the Variant Interpretation for Cancer Consortium (VICC) MetaKB. CIViC supports the application of AMP/ASCO/CAP tiering and levels for clinical significance Assertions. CIViC recently created Oncogenic Assertions, which supports the application of ClinGen/CGC/VICC codes. Three SC-VCEPs (FGFR, FLT3, and Histone H3) are tailoring the ClinGen/CGC/VICC Oncogenicity guidelines to their specific genes and CIViC will enable their ClinGen-approved, modified codes to be applied directly to their Oncogenic Assertions. Also, two SC-VCEPs (NTRK and BCR::ABL1-like) are developing fusion specific oncogenicity classification guidelines, which will be applied to their fusion specific CIViC Oncogenic Assertions. ClinGen Somatic groups have generated 695 CIViC Evidence Items and 33 Assertions from over 400 published papers. These numbers will continue to grow along with the development of more SC-VCEPs. ClinGen Somatic and CIViC foster collaboration, innovation, and most importantly the advancement of precision medicine. Citation Format: Jason Saliba, Arpad Danos, Kilannin Krysiak, Adam Coffman, Susanna Kiwala, Joshua McMichael, Cameron J. Grisdale, Ian King, Shamini Selvarajah, Xinjie Xu, Rashmi Kanagal-Shamanna, Laveniya Satgunaseelan, David Meredith, Mark Evans, Charles G. Mullighan, Yassmine Akkari, Gordana Raca, Angshumoy Roy, Alex H. Wagner, Ramaswamy Govindan, Obi L. Griffith, Malachi Griffith, on behalf of the ClinGen Somatic Clinical Domain Working Group. ClinGen Somatic and CIViC collaborate to comprehensively evaluate somatic variants in cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6569.
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
D’Amico, Thomas A., Bentrem, David J., Cooke, David J. , Corvera, Carlos U. , Das, Prajnan , Enzinger, Peter C. , Enzler, Thomas , Farjah, Farhood , Gerdes, Hans, Grierson, Patrick , Hofstetter, Wayne L. , Ilson, David H. , Jalal, Shadia I. , Keswani, Rajesh N. , Kleinberg, Lawrence , Lacy, Jill , Licciardi, Frank, Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael, Miller, Aaron , Mukherjee, Sarbajit , Mulcahy, Mary F. , Poultsides, George A. , Reznik, Scott I. , Roses, Robert E. , Strong, Vivian E. , Su, Stacey, Wang, Hanlin L. , Wiesner, Georgia L. , Willett, Christopher G. , Yakoub, Danny , Yoon, Harry H. , McMillian, Nicole R., Pluchino, Lenora A. , Yoon, Harry, Ajani, Jaffer A. , Cooke, David, Gerdes, Hans, Gibson, Michael K. , Kim, Sunnie S. Y. , Klempner, Samuel J. , Miller, Aaron, Outlaw, Darryl Alan , Perry, Kyle A. , Pimiento, José M.

Journal of the National Comprehensive Cancer Network | April 4, 2023 | Volume: 21 | Issue: 4 | Pages: 393-422

10.6004/jnccn.2023.0019 | PMID 37015332 Get It

Cancers originating in the esophagus or esophagogastric junction constitute a major global health problem. Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics, and prognosis. In contrast to esophageal adenocarcinoma, which usually affects the lower esophagus, esophageal SCC is more likely to localize at or higher than the tracheal bifurcation. Systemic therapy can provide palliation, improved survival, and enhanced quality of life in patients with locally advanced or metastatic disease. The implementation of biomarker testing, especially analysis of HER2 status, microsatellite instability status, and the expression of programmed death-ligand 1, has had a significant impact on clinical practice and patient care. Targeted therapies including trastuzumab, nivolumab, ipilimumab, and pembrolizumab have produced encouraging results in clinical trials for the treatment of patients with locally advanced or metastatic disease. Palliative management, which may include systemic therapy, chemoradiation, and/or best supportive care, is recommended for all patients with unresectable or metastatic cancer. Multidisciplinary team management is essential for all patients with locally advanced esophageal or esophagogastric junction cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on the management of recurrent or metastatic disease.
Editorial Commentary
Hanna, Kevin F. , Koo, Kevin

Urology Practice | April 4, 2023 | Volume: 10 | Issue: 3 | Pages: 277-277

10.1097/upj.0000000000000396.01 | PMID 37103510 Get It

Patient and Process Outcomes among Pediatric Patients Undergoing Appendectomy during the COVID-19 Pandemic: An International Retrospective Cohort Study
Matava, Clyde , Tighe, Nathaniel T. G. , Baertschiger, Reto M. , Wilder, Robert T., Correll, Lynnie , Staffa, Steven J. , Kato, Meredith , Meier, Petra M. , Raman, Vidya T. , Roque, Remigio A. , Zhong, John , Edala, Thejovathi , Greer, Timothy J. , Ungern‐Sternberg, Britta S. von , Simpao, Allan F. , Collaborators, for the PEACOC, Zurakowski, David , Reddy, Srijaya K. , Peterson, Melissa Brooks , Cravero, Joseph P. , Collaborators, for the PEACOC

Anesthesiology | April 4, 2023 | Volume: 139 | Issue: 1 | Pages: 35-48

10.1097/aln.0000000000004570 | PMID 37014980 Get It

Background COVID-19 forced healthcare systems to make unprecedented changes in clinical care processes. The authors hypothesized that the COVID-19 pandemic adversely impacted timely access to care, perioperative processes, and clinical outcomes for pediatric patients undergoing primary appendectomy. Methods A retrospective, international, multicenter study was conducted using matched cohorts within participating centers of the international PEdiatric Anesthesia COVID-19 Collaborative (PEACOC). Patients younger than 18 yr old were matched using age, American Society of Anesthesiologists Physical Status, and sex. The primary outcome was the difference in hospital length of stay of patients undergoing primary appendectomy during a 2-month period early in the COVID-19 pandemic (April to May 2020) compared with prepandemic (April to May 2019). Secondary outcomes included time to appendectomy and the incidence of complicated appendicitis. Results A total of 3,351 cases from 28 institutions were available with 1,684 cases in the prepandemic cohort matched to 1,618 in the pandemic cohort. Hospital length of stay was statistically significantly different between the two groups: 29 h (interquartile range: 18 to 79) in the pandemic cohort versus 28 h (interquartile range: 18 to 67) in the prepandemic cohort (adjusted coefficient, 1 [95% CI, 0.39 to 1.61]; P < 0.001), but this difference was small. Eight centers demonstrated a statistically significantly longer hospital length of stay in the pandemic period than in the prepandemic period, while 13 were shorter and 7 did not observe a statistically significant difference. During the pandemic period, there was a greater occurrence of complicated appendicitis, prepandemic 313 (18.6%) versus pandemic 389 (24.1%), an absolute difference of 5.5% (adjusted odds ratio, 1.32 [95% CI, 1.1 to 1.59]; P = 0.003). Preoperative SARS-CoV-2 testing was associated with significantly longer time-to-appendectomy, 720 min (interquartile range: 430 to 1,112) with testing versus 414 min (interquartile range: 231 to 770) without testing, adjusted coefficient, 306 min (95% CI, 241 to 371; P < 0.001), and longer hospital length of stay, 31 h (interquartile range: 20 to 83) with testing versus 24 h (interquartile range: 14 to 68) without testing, adjusted coefficient, 7.0 (95% CI, 2.7 to 11.3; P = 0.002). Conclusions For children undergoing appendectomy, the COVID-19 pandemic did not significantly impact hospital length of stay. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis
Kugelmas, Marcelo , Loftus, Michelle, Owen, Emily , Wadei, Hani M. , Saab, Sammy , Wadei, Hani, Wadei, Hani M

American Journal of Health-System Pharmacy | April 4, 2023 | Volume: 80 | Issue: 13 | Pages: 806-817

10.1093/ajhp/zxad070 | PMID 37013893 Get It

Abstract Purpose Albumin, the most abundant and arguably most important protein in the human body, plays a unique role in decompensated cirrhosis because its structure and function are quantitatively and qualitatively affected. A literature review was performed to provide insights into albumin use. The manuscript was developed using a multidisciplinary approach; 2 hepatologists, a nephrologist, a hospitalist, and a pharmacist, who are all members of or work closely with the Chronic Liver Disease Foundation, collaborated to write this expert perspective review. Summary Cirrhosis represents the potential end in the spectrum of all chronic liver diseases. Decompensated cirrhosis, defined by the overt manifestation of liver failure (eg, ascites, hepatic encephalopathy, variceal bleeding), is the inflection point associated with increased mortality. Human serum albumin (HSA) infusion serves an important role in the treatment of advanced liver disease. The benefits of HSA administration in patients with cirrhosis are widely accepted, and its use has been advocated by several professional societies. However, inappropriate HSA use can lead to significant adverse patient events. This paper discusses the rationale for the administration of HSA in the treatment of complications of cirrhosis, analyzes the data on the use of HSA in cirrhosis, and streamlines practical recommendations set forth in published guidance. Conclusion Use of HSA in clinical practice needs to be improved. The objective of this paper is to empower pharmacists to facilitate and improve the use of HSA in patients with cirrhosis at their practice sites.
A novel application of finite Gaussian mixture model (GMM) using real and simulated biomarkers of cardiovascular disease to distinguish adolescents with and without obesity
Hossain, Jobayer , Balagopal, Prabhakaran

Communications in Statistics: Case Studies, Data Analysis and Applications | April 4, 2023 | Volume: 9 | Issue: 1 | Pages: 106-120

10.1080/23737484.2023.2194249 Get It

MicroRNAs as a therapeutic target in IgA nephropathy in Indian population
Tripathy, Anindita, Poornachandra, Yedla , Vishnubhotla, Ravikanth, Sekaran, Anuradha , Reddy, Sai Keithi, Keithi Reddy, Sai Ram

Biomedical Reports | April 4, 2023 | Volume: 18 | Issue: 5 | Pages: No page available

10.3892/br.2023.1617 | PMID 37089577 Get It

Barriers to head and neck cancer care in high-income and low- and middle-income countries: a scoping review
Sprow, Holly N. , Heer, Baveena, Jashek‐Ahmed, Farizeh , Wiedermann, Joshua P. , Seguya, Amina , Wiedermann, Joshua , Nuss, Sarah

Current Opinion in Otolaryngology & Head & Neck Surgery | April 4, 2023 | Volume: 31 | Issue: 3 | Pages: 185-193

10.1097/moo.0000000000000889 | PMID 37014803 Get It

Purpose of review Identify patient-perceived barriers to head and neck cancer care and compare differences in barriers by country income status. Recent Findings Of the 37 articles, 51% (n = 19) were from low- and middle-income countries (LMICs), while 49% (n = 18) were from high-income countries. Of the papers from high-income countries, unspecified head and neck cancer (HNC) subtype (67%, n = 12) were the most common cancer type, while upper aerodigestive tract mucosal malignancies (58%, n = 11) were more common in LMICs (P = 0.02). Based on World Health Organization barriers, level of education (P = < 0.01) and alternative medicine use (P = 0.04) were greater barriers in LMICs compared to high-income countries. At least 50% of articles listed barriers at all three ‘Three Delays’ timepoints. There were no significant differences by country income status for the ‘Three Delays’ timepoints of deciding to seek care (P = 0.23), reaching the healthcare facility (P = 0.75), or receiving care (P = 1.00). Summary Patients face barriers to care for head and neck cancer regardless of country income status. There is overlap in several barriers and a need for systemic improvement in access. The differences in education and alternative medicine may guide region-specific interventions to improve the provision of head and neck services.
Geographic and Demographic Disparities in Colorectal Cancer: A National Cancer Database Analysis
Mohammed, Turab , Gosain, Rohit , Rana, Navpreet, Lemini, Riccardo , Wang, Katy, Agha, A., Neupane, Arun , Nurkin, Steven, Gabriel, Emmanuel , Boland, Patrick M.

Hematology/Oncology and Stem Cell Therapy | April 4, 2023 | Volume: 16 | Issue: 3 | Pages: 262-271

10.56875/2589-0646.1061 | PMID 37023221 Get It

Background and objectives: Area of residence may adversely affect survival and outcomes in many cancers. The objective of this study was to evaluate the impact of geographical and demographic disparities on survival of patients with colorectal cancer. Materials and methods: Data were obtained from the National Cancer Database (NCDB) colon, rectosigmoid, and rectal datasets. Patients were categorized by area of residence, namely, metropolitan (MA), urban (UA), or rural (RA). Sociodemographic and tumor-related data were collected and analyzed to evaluate variables affecting overall survival (OS). Results: In total, 973,139 patients between 2004 and 2013 were included in the study, of which 83%, 15%, and 2% were MA, UA, and RA residents, respectively. RA and UA patients were mostly white male with low income and no comorbidities. In univariate analysis, OS was worse for RA (hazard ratio [HR] 1.10) and UA (HR 1.06) colorectal cancer patients than that for MA colorectal cancer patients. In multivariate analysis revealed significant association between OS and geographic residence, with worse OS for RA (HR 1.02, p = 0.04) and UA (HR 1.01, p = 0.003) patients. Black (HR 1.14) and Native American (HR 1.17) patients had worse outcomes, while Asians (HR 0.8), women (HR 0.88), and patients with higher income had improved OS (HR 0.88). Conclusion: The differences in the OS for RA and UA patients with colorectal cancer were significantly driven by economic disparity. Area of residence represents an important factor independently limiting access to care, particularly in geographically isolated individuals.
Myocardial Inflammation as a Manifestation of Genetic Cardiomyopathies: From Bedside to the Bench
Peretto, Giovanni , Resta, Chiara Di , Rabino, Martina , Villatore, Andrea , Lazzeroni, Davide , Sala, Simone , Cooper, Leslie T. , Di Resta, Chiara , Villatore, Andrea , Lazzeroni, Davide , Sala, Simone , Cooper, Leslie T , Sommariva, Elena , Pompilio, Giulio

Biomolecules | April 4, 2023 | Volume: 13 | Issue: 4 | Pages: 646

10.3390/biom13040646 | PMID 37189393 Get It

Over recent years, preclinical and clinical evidence has implicated myocardial inflammation (M-Infl) in the pathophysiology and phenotypes of traditionally genetic cardiomyopathies. M-Infl resembling myocarditis on imaging and histology occurs frequently as a clinical manifestation of classically genetic cardiac diseases, including dilated and arrhythmogenic cardiomyopathy. The emerging role of M-Infl in disease pathophysiology is leading to the identification of druggable targets for molecular treatment of the inflammatory process and a new paradigm in the field of cardiomyopathies. Cardiomyopathies constitute a leading cause of heart failure and arrhythmic sudden death in the young population. The aim of this review is to present, from bedside to bench, the current state of the art about the genetic basis of M-Infl in nonischemic cardiomyopathies of the dilated and arrhythmogenic spectrum in order to prompt future research towards the identification of novel mechanisms and treatment targets, with the ultimate goal of lowering disease morbidity and mortality.